Skip to content

Assessment of Viola Odorata efficacy on insomnia in patients with obsessive compulsive disorder or depression

The effectiveness of violet syrup on insomnia reduction in patients with obsessive compulsive disorder or depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017040833294N1
Enrollment
80
Registered
2017-09-26
Start date
2017-09-15
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Obsessive Compulsive Disorder. Condition 2: Insomnia. Condition 3: Depression. Condition 4: Insomnia. Obsessive Compulsive Disorde Insomnia Depression Insomnia

Interventions

Intervention 1: Drug use syrup of violets to 5 ml every 12 hours in the morning and at night. Intervention 2: Placebo syrup use to 5 ml every 12 hours in the morning and at night.
Treatment - Drugs
Placebo
Drug use syrup of violets to 5 ml every 12 hours in the morning and at night.
Placebo syrup use to 5 ml every 12 hours in the morning and at night.

Sponsors

Vice chancellor for research, Deputy of Research and Technology of Shahed University
Lead Sponsor
Vice chancellor for research, Deputy of Research and Technology of Shahed University
Collaborator

Eligibility

Sex/Gender
All
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: no history of psychotic psychiatric disorder and generalized anxiety disorder, no history of opiate using and neurological diseases such as Parkinson and Alzheimer, no sleep apnea, lack of simultaneous use of pharmaceutical and non- pharmaceutical treatments for insomnia, no pregnancy and lactation Exclusion criteria: history of physical illness along with pulmonary diseases, rhinitis allergy, cardiovascular diseases, infectious diseases, hepatic and renal failure, cancers, psychiatric disorder and generalized anxiety disorder; history of smoking and opiate using, history of neurological diseases such as Parkinson and Alzheimer, sleep apnea, simultaneous use of pharmaceutical and non- pharmaceutical treatments for insomnia, pregnant and lactating women, drug avoidance for >20% of total dosage of prescribed drug

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Insomnia. Timepoint: Before intervention (baseline), after one month (post). Method of measurement: Pittsburgh Questionnaire.

Secondary

MeasureTime frame
Depression. Timepoint: Before intervention (baseline), after one month (post). Method of measurement: Beck Questionnaire.;Obsessive Compulsive Disorder. Timepoint: Before intervention (baseline), after one month (post). Method of measurement: YBOCS Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Shayesteh

Iranian Traditional Medicine Department, Shahed University

m.shayesteh@shahed.ac.ir dr.maryamshayesteh@yhoo.com+98 21 5121 4055

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026